GSK2983559

GSK2983559

• UNSPSC Description: GSK2983559 is an orally active and potent receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 blocks many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples[1].
• Target Antigen: RIP kinase
• Type: Reference compound
• Related Pathways: Apoptosis
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/gsk2983559.html
• Purity: 98.82
• Solubility: DMF : < 1 mg/mL (ultrasonic;warming;heat to 80°C)|DMSO : < 1 mg/mL (ultrasonic;warming;heat to 80°C)|Ethanol : < 1 mg/mL (ultrasonic)
• Smiles: CC(C)(C)S(C(C(OCCOP(O)([O-])=O)=CC1=NC=N2)=CC1=C2NC3=CC(N=CS4)=C4C=C3)(=O)=O.[H]O[H].[H]O[H].[H]O[H].[Ca+2]
• Molecular Weight: 612.63
• References & Citations: [1]Pamela A Haile, et al. Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. J Med Chem. 2019 Jul 25;62(14):6482-6494.|[2]Shuwei Wu, et al. Design, synthesis, and structure-activity relationship of novel RIPK2 inhibitors. Bioorg Med Chem Lett. 2022 Sep 2;75:128968.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, sealed storage, away from moisture)
• Clinical Information: Phase 1